Bando H, Kotani D, Satake H, Hamaguchi T, Shiozawa M, Kotaka M, Masuishi T, Yasui H, Kagawa Y, Komatsu Y, Oki E, Yamamoto Y, Kawakami H, Misumi T, Taniguchi H, Yamazaki K, Muro K, Yoshino T, Kato T, Tsuji A. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC. Med. 2024: S2666-6340(24)00216-2. doi: 10.1016/j.medj.2024.05.012.https://www.cell.com/med/fulltext/S2666-6340(24)00216-2#
Nair T, Ray S, George J, Pande A. Efficacy of Trimetazidine in the Prevention of Contrast-Induced Nephropathy in Patients Undergoing Contrast Coronary Intervention: A Systematic Review and Meta-Analysis (PRISMA). Journal of Clinical Medicine. 2024;13(7):2151. doi: 10.3390/jcm13072151. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11012740/pdf/jcm-13-02151.pdf
Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, Masuda H, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Kosaka N, Tajima K, Masuda N. Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast Cancer 2024. doi: 10.1007/s12282-024-01575-5. https://link.springer.com/article/10.1007/s12282-024-01575-5
Sonoyama T, Iwata S, Shinkai M, Iwata-Yoshikawa N, Shiwa-Sudo N, Hemmi T, Ainai A, Nagata N, Matsunaga N, Tada Y, Homma T, Omoto S, Yokokawa Shibata R, Igarashi K, Suzuki T, Hasegawa H, Ariyasu M. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults. Vaccine. 2023;41(11):1834-1847. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755034/pdf/main.pdf
Meng F, Li W, Zhi F, Li Z, Xue Z, He S, Chen W, Chen Y, Xing X, Yao C, Wu Y, Zhang S. Antiperistaltic effect and safety of l-menthol oral solution on gastric mucosa for upper gastrointestinal endoscopy in Chinese patients: Phase III, multicenter, randomized, double-blind, placebo-controlled study. Digestive Endoscopy. 2021;33(7):1110-1119. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596731/pdf/DEN-33-1110.pdf
Takeuchi Y, Saito H, Makishima M, Yokoyama H, Yamaguchi T, Fujii H, Inoue E, Isemura T, Kondo S. Long-term safety of eldecalcitol in Japanese patients with osteoporosis: a retrospective, large-scale database study. Journal of Bone and Mineral Metabolism. 2022;40(2):275-291. https://pubmed.ncbi.nlm.nih.gov/35041084/
Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S, Igarashi K, Ariyasu M. Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings. Vaccine. 2022;40(27):3721-3726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122779/pdf/main.pdf
Shinkai M, Sonoyama T, Kamitani A, Shibata RY, Seki NM, Omoto S, Shinoda M, Sato T, Ishii N, Igarashi K, Ariyasu M. Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study. Vaccine. 2022;40(32):4328-4333. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212435/pdf/main.pdf
Miyazawa S, Takazono T, Hosogaya N, Yamamoto K, Watanabe H, Fujiwara M, Fujita S, Mukae H. Comparison of intra-familial transmission of influenza virus from index patients treated with baloxavir marboxil or oseltamivir using an influenza transmission model and a health insurance claims database. Clinical Infectious Diseases. 2022;75(6):927-935. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522426/pdf/ciac068.pdf
Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults. Antimicrobial Agents and Chemotherapy. 2022;66(10):e0063222. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578392/pdf/aac.00632-22.pdf
Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50). Esophagus. 2023;20(2):291-301. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024660/pdf/10388_2022_Article_970.pdf
Uchino Y, Uchino M, Mizuno M, Shigeno Y, Furihata K, Shimazaki J. Morphological alterations in corneal nerves of patients with dry eye and associated biomarkers. Experimental Eye Research. 2023;230:109438. https://pubmed.ncbi.nlm.nih.gov/36933693/
Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuzaki T, Matsuo Y, Kubota R. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults. Clinical Drug Investigation. 2023;43(5):335-346. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177727/pdf/40261_2023_Article_1265.pdf
Sato S, Tomitori H, Okawa A, Akano K. Prescription patterns of analgesics in cancer patients with bone metastases in Japan: a retrospective database study. International Journal of Clinical Oncology. 2023; Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/37314600/